BiondVax to present immunoassay workshop at EDUFULVAC event
EDUFULVAC is a European consortium assembled by the European Vaccine Initiative in Germany and the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH) in the United States.
BiondVax develops and commercializes immunomodulation therapies for infectious diseases.
"This invitation is further recognition by the European Commission and the NIH of BiondVax's central position and contribution to this important field of new influenza vaccine development," BiondVax CEO Ron Babecoff said. "Our scientific and clinical experience is well recognized both in Europe and in the U.S. We hope that together with the other participants, we can facilitate the acceptance of new standard assays that will promote regulatory approval for universal flu vaccines."
The workshop will include participants from research institutions, industry, public health and regulatory agencies that will discuss immunoassays that could be used to assess broadly reactive or universal influenza vaccines and their standardization.
BiondVax Chief Scientist Tamar Ben-Yedidia will give a presentation on the company's experience and views on assays for the assessment of future vaccines.